Indivior PLC (INDV) — 8-K Filings

8-K Filings (18)

• 8-K Filing — Dec 22, 2025
• Indivior PLC Reports Executive and Director Changes — Dec 18, 2025 Risk: medium
  On December 12, 2025, Indivior PLC filed an 8-K report detailing changes in its executive officers and board of directors. The filing indicates a departure of c
• 8-K Filing — Dec 15, 2025
• Indivior PLC Terminates Material Definitive Agreement — Nov 20, 2025 Risk: medium
  Indivior PLC announced on November 20, 2025, the termination of a material definitive agreement. The filing also includes Regulation FD disclosures and financia
• 8-K Filing — Nov 14, 2025
• Indivior PLC Files 8-K on Financials and Operations — Oct 30, 2025 Risk: low
  Indivior PLC filed an 8-K on October 30, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statement
• Indivior PLC Files 8-K Current Report — Oct 1, 2025 Risk: low
  Indivior PLC filed an 8-K on October 1, 2025, to report current information. The filing primarily serves as a notification of events and does not contain specif
• Indivior PLC Reports Exit/Disposal Costs — Aug 26, 2025 Risk: medium
  On August 26, 2025, Indivior PLC filed an 8-K report detailing costs associated with exit or disposal activities. The filing does not specify the exact nature o
• Indivior Appoints New Chief Medical Officer — Aug 22, 2025 Risk: low
  On August 20, 2025, Indivior PLC announced the appointment of Dr. Christian Angel as Chief Medical Officer, effective September 1, 2025. Dr. Angel will receive
• Indivior PLC Files 8-K on Financials — Jul 31, 2025 Risk: low
  On July 31, 2025, Indivior PLC filed an 8-K report detailing results of operations and financial condition, along with Regulation FD disclosures and financial s
• Indivior PLC Files 8-K for June 30, 2025 — Jun 30, 2025 Risk: low
  Indivior PLC filed an 8-K on June 30, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and fina
• Indivior PLC Appoints New Chief Medical Officer — Jun 24, 2025 Risk: medium
  Indivior PLC announced on June 20, 2025, the departure of its Chief Medical Officer, Dr. Robert L. Johnson, effective June 20, 2025. The company also announced
• Indivior PLC Files 8-K Report — Jun 2, 2025 Risk: low
  On June 2, 2025, Indivior PLC filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific fin
• Indivior PLC Files 8-K: Other Events & Exhibits — Jun 2, 2025 Risk: low
  Indivior PLC filed an 8-K on June 2, 2025, reporting events as of May 30, 2025. The filing is primarily for 'Other Events' and includes 'Financial Statements an
• Indivior PLC Files 8-K: Director Changes, Officer Appointments, Bylaw Amendments — May 8, 2025 Risk: medium
  On May 8, 2025, Indivior PLC filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the election of new
• Indivior Acquires Opiant Pharmaceuticals for $145M — Apr 24, 2025 Risk: medium
  Indivior PLC announced on April 24, 2025, that it has completed the acquisition of Opiant Pharmaceuticals, Inc. for an aggregate purchase price of approximately
• Indivior PLC Files 8-K Report — Mar 27, 2025 Risk: low
  On March 27, 2025, Indivior PLC filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and the filing of Financial Sta
• Indivior PLC CFO Departs, Interim Appointed — Mar 4, 2025 Risk: medium
  On March 2, 2025, Indivior PLC announced the departure of its Chief Financial Officer, Ryan Wm. Tomczyk, effective March 15, 2025. The company also announced th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX